Cardiovascular risks of antiretroviral therapy

New England Journal of Medicine

Volumn 356, Issue 17, 2007, Pages 1773-1775

  Stein, James H ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACUTE HEART INFARCTION; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DRUG POTENTIATION; DYSLIPIDEMIA; EDITORIAL; ENDOTHELIAL DYSFUNCTION; FOLLOW UP; HEART INFARCTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITAL ADMISSION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; PRIORITY JOURNAL; TREATMENT OUTCOME; VASCULAR DISEASE;

EID: 34247476743     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe078037     Document Type: Editorial

References (9)

1. Passalaris JD, Sepkowitz KA, Glesby MJ. Coronary artery disease and human immunodeficiency virus infection. Clin Infect Dis 2000;31:787-97.
2. Maggi P, Fiorentino G, Epifani G, et al. Premature vascular lesions in HIV-positive patients: a clockwork bomb that will explode? AIDS 2002;16:947-8.
3. Stein JH. Managing cardiovascular risk in patients with HIV infection. J Acquir Immune Defic Syndr 2005;38:115-23.
4. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA. Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 2003;348:702-10.
5. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96.
6. Stein JH, Cotter BR, Parker RA, et al. Antiretroviral therapy improves endothelial function in individuals with human immunodeficiency virus infection: a prospective, randomized multicenter trial (Adult AIDS Clinical Trials Group Study A5152s). Circulation 2005;112:II-237. abstract.
7. The DAD Study Group. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007;356:1723-35.
8. Currier J, Kendall M, Henry K, et al. 3-Year follow-up of carotid intima-media thickness in HIV-infected and uninfected adults: ACTG 5078. Presented at the 13th Conference on Retroviruses and Opportunistic Infections, Denver, February 5-8, 2006. abstract.
9. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. [Erratum, Circulation 2004;110:763.]